Quick Answer
UroGen Pharma Ltd. reported Operating Income of -$124.86 million for fiscal year 2025.
UroGen Pharma Ltd. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$124.86M | -29.0% |
| 2024 | -$96.78M | -47.7% |
| 2023 | -$65.54M | +17.1% |
| 2022 | -$79.04M | +14.4% |
| 2021 | -$92.29M | +27.2% |
| 2020 | -$126.74M | -15.8% |
| 2019 | -$109.48M | -41.8% |
| 2018 | -$77.18M | -286.9% |
| 2017 | -$19.95M | -2600.0% |
| 2016 | $798.0K | +106.4% |
| 2015 | -$12.41M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$27.39M | -56.1% | +33.9% |
| June 30, 2025 | -$41.45M | -60.4% | -12.3% |
| March 31, 2025 | -$36.91M | -43.4% | -110.4% |
| September 30, 2024 | -$17.55M | -30.0% | +32.1% |
| June 30, 2024 | -$25.84M | -68.0% | -0.4% |
| March 31, 2024 | -$25.74M | -16.8% | -90.7% |
| September 30, 2023 | -$13.50M | +25.4% | +12.2% |
| June 30, 2023 | -$15.38M | +17.8% | +30.2% |
- UroGen Pharma Ltd. showed a decrease of -29.0% in Operating Income compared to the prior fiscal year.
- Over the 2015–2025 period, UroGen Pharma Ltd.’s operating income has declined by 906.1% (from -$12.41 million to -$124.86 million).
- The most recent figure is from UroGen Pharma Ltd.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: